Generate:Biomedicines

Rounds and research, on one timeline

1. 2026-10-27
   Research

   Level 4 · Tested in the physical world

   Generate:Biomedicines cuts a CAR's signalling tail to 45 amino acids, under a third of the clinical design, and reports stronger function

   Shortening the tail was expected to cost function, because more activation motifs were read as stronger signalling. The short tail made more receptor per unit of mRNA, which is why the team could put four receptors on one dose, and the report suggests compact tails may lower the dose needed to make CAR T cells inside the body. It is also a worked case of agent-guided design: the agents proposed designs and revised them as measurements came in.

   Timeline entry →generatebiomedicines.com ↗

2. 2026-02-26IPO
   Round

   $400M

   For: public listing on Nasdaq

   Not stated

   25M shares at $16; underwriters hold a 30-day option on 3.75M more; Goldman Sachs and Morgan Stanley lead books.

   No investor named in the source.

   By this date the record held 2 research entries, highest level 5

   Announced by the company · generatebiomedicines.com ↗On the timeline →

3. 2025-12-01
   Research

   Level 5 · Used in practice

   Generate:Biomedicines takes an AI-optimised asthma antibody into two Phase 3 trials

   Phase 3 tests the drug, not the design method. No efficacy data yet, and the AI role is the company's own account.

   Timeline entry →kyodonewsprwire.jp ↗

4. 2023-11-15
   Research

   Level 4 · Tested in the physical world

   Generate:Biomedicines publishes Chroma, a diffusion model that writes new protein structures and sequences to order, and makes 310 of its designs in the lab

   The record holds Generate's IPO, its Phase 3 asthma antibody and its deals, but not its main published method. Chroma puts the design conditions into the sampling itself, so one model takes a symmetry, a shape or a text prompt where otherwise each would need its own tool, and its code is open for others to test.

   Timeline entry →doi.org ↗

5. 2023-09-14Series C
   Round

   $273M

   For: multi-year runway to advance clinical programs and the platform

   Toward the clinicModels and platform

   No lead named; Fierce Biotech's headline calls it a down round, with no valuation figure given.

   AmgenNVentures (NVIDIA) ✓MAPS Capital (Mirae Asset)Pictet Alternative AdvisorsFlagship Pioneering ✓FidelityADIA (subsidiary)T. Rowe PriceARCH Venture Partners ✓March Capital

   Announced by the company · generatebiomedicines.com ↗

6. 2021-11-18Series B
   Round

   $370M

   For: evolve the platform, scale the team, move programs toward IND

   Models and platformHiringToward the clinic

   Called the company's first external equity raise; Flagship is the founder rather than a named lead.

   Flagship Pioneering ✓ADIA (subsidiary)Alaska Permanent FundARCH Venture Partners ✓FidelityT. Rowe PriceMorningside VenturesAltitude Life Science Ventures ✓

   Announced by the company · generatebiomedicines.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →